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Pharmacokinetics of ibuprofen in man. I. Free and total 
area/dose relationships 
Ibuprofen kinetics were studied in 15 subjects after four oral doses. Plasma levels of both total 
and free ibuprofen were measured for 12 hr, and urine was collected for 48 hr after the doses. 
All subjects showed a nonlinear relationship between dose and total ibuprofen plasma AUC. 
Free ibuprofen plasma AUC, however, was linearly related to the dose, suggesting that oral 
clearance based on free drug was dose independent. Urinary recovery data indicated that 
efficiency of absorption was dose independent. 
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Ibuprofen [dl-2-(p-isobutylphenyl)propionic 
acid] is a propionic acid derivative with potent 
anti-inflammatory properties. It is used exten- 
sively in long-term oral treatment of rheumatoid 
arthritis and osteoarthritis. The pharmacology 
and metabolism of ibuprofen in man and other 
species have been reported.l. 7 It has been dem- 
onstrated that ibuprofen is highly (>99%) 
plasma-protein bound.4' 7' 9 The manufacturer's 
package insert* presently specifies that ibupro- 
fen shows nonlinear kinetics inasmuch as total 
plasma AUC increases less than proportionately 
with the given dose. Our aim was to discover 
the cause of the observed nonlinear kinetics. 
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Methods 
Our subjects were 15 white men ranging in 
age from 22 to 35 yr (mean = 25), with mean 
body weight, 78.2 kg (69.8 to 83.5); height, 
1.84 m (1.73 to 1.93); and body surface area, 
2.01 m2 (1.89 to 2.24 estimated by nomogram). 
The normal subjects were selected from respon- 
dents to an advertisement based on established 
criteria, namely, subject availability, reliability, 
medical history, physical examination, and the 
results of blood and urinary analyses. Subjects 
could not participate if they were taking other 
medications, had upper gastrointestinal dis- 
eases, were renally or hepatically impaired, or 
were known to be hypersensitive to ibuprofen. 
Subjects were asked to refrain from the use of 
other medications during the study. All subjects 
signed consent forms. 
Each subject was assigned to one of three 
groups and received one of three treatments (A, 
B, or .c) sequentially over the first 3 wk of the 
4-wk study period. Treatments A, B, and C 
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Table I. Mean plasma concentrations of total and free ibuprofen with their SEs after 
one, two, and three 400-mg tablets 
*Numbers in parentheses are SEs. 
consisted of one, two, or three 400-mg ibupro- 
fen tablets (Motrin), which were given to the 
groups in accordance with a Latin square de- 
sign. In the final week of the study all subjects 
received treatment D, which consisted of 20 ml 
oral ibuprofen solution (20 mg/ml ibuprofen). 
All medication was taken with 6 ounces of wa- 
ter, and tablets were swallowed whole. All 
medication was taken at 7 A.M., the subjects 
having fasted since 10 P.M. the previous night. 
No food or beverages were permitted until 4 hr 
after the drug was given, at which time a stan- 
dard lunch was provided. Assay of the dosage 
forms before the drug was given showed that 
actual doses were as follows: treatment A, 401 
mg; treatment B, 802 mg; treatment C, 1203 
mg; and treatment D, 420 mg. These doses 
were used in the estimation of clearance (Cl) 
and urinary recovery. 
Blood samples were drawn by sequential ve- 
nipuncture into Vacutainer tubes containing di- 
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sodium edetate as an anticoagulant. For treat- 
ments A to C, 5-ml blood samples were drawn 
at 0, 0.167, 0.33, 3, 10, and 12 hr, and 10-ml 
samples were drawn at 0.5, 1, 1.5, 2, 4, 6, and 
8 hr. For treatment D, 5-ml blood samples were 
drawn at 0, 0.083, 0.167, 0.25, 0.333, and 3 
hr, and 10-ml samples were drawn at 0.5, 1, 
1.5, 2, 4, 6, and 8 hr. The sampling scheme 
after the tablets was different from that follow- 
ing the solution, since we knew from previous 
studies that the drug in solution is absorbed 
more rapidly than the drug in tablet form. Each 
blood sample was rapidly separated into plasma 
and cellular components by centrifugation and 
the plasma was then harvested and frozen until 
assayed. Plasma obtained from the 10-ml blood 
samples was divided into two aliquots; half was 
used for the HPLC plasma ibuprofen assay and 
half for the ibuprofen protein-binding study. 
Total urine samples were collected over the 
following intervals: 0 to 6, 6 to 12, 12 to 24, 24 
Time 
(hr) 
Total concentration (1)..glml) = Free concentration ( g I ml) 
One tablet Two tablets Three tablets One tablet Two tablets Three tablets 
0.167 0.16 0.20 0.29 0.79 0.92 1.40 
(0.11)* (0.14) (0.23) (0.56) (0.64) (1.16) 
0.333 6.58 4.46 7.28 35.0 23.1 64.2 
(2.47) (1.66) (2.54) (14.0) (8.99) (26.16) 
0.5 17.6 18.2 28.6 96.6 98.3 227 
(3.84) (3.96) (6.26) (22.0) (22.0) (72.8) 
1.0 27.5 44.6 63.8 156 279 462 
(3.80) (5.54) (9.96) (22.6) (38.7) (78.8) 
1.5 28.3 50.9 62.7 162 326 453 
(3.23) (4.10) (7.40) (22.0) (33.7) (64.2) 
2.0 25.6 52.1 68.8 143 329 457 
(2.55) (2.15) (4.37) (15.6) (20.0) (43.7) 
3.0 20.0 35.3 50.2 108 205 311 
(1.48) (2.34) (4.17) (9.42) (16.2) (36.9) 
4.0 14.3 23.6 34.8 74.7 130 195 
(1.12) (1.81) (2.89) (6.86) (11.7) (20.5) 
6.0 7.05 11.3 16.1 36.0 58.4 81.3 
(0.74) (0.78) (1.47) (4.09) (4.71) (8.37) 
8.0 3.48 5.68 7.71 17.5 28.7 38.1 
(0.41) (0.53) (0.71) (2.27) (2.95) (3.94) 
10.0 1.95 2.84 4.09 9.73 14.1 19.8 
(0.22) (0.35) (0.36) (1.19) (1.85) (1.93) 
12.0 1.14 1.80 2.04 5.98 8.90 11.0 
(0.17) (0.28) (0.31) (0.83) (1.40) (1.26) 
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to 36, and 36 to 48 hr. The volume of each 
sample was recorded and a 50-ml aliquot of 
each was frozen until just before it was assayed. 
The 13 plasma samples obtained from each 
subject during each phase were subjected to 
specific HPLC assay for ibuprofen as previously 
described.' Urine samples were assayed for free 
and conjugated drug and metabolites by the 
previously described gradient HPLC system.' 
An estimation of free ibuprofen concentra- 
tions in plasma samples was gained by subject- 
ing 7 of the 13 samples to equilibrium dialysis 
and then using these data and the HPLC assays 
on the other samples to estimate free concentra- 
tions for all samples. A detailed account of 
methods will be presented in a future report6 
and is also explained by equations No. 5 and 
No. 10 of Behm and Wagner.' 
Results 
Mean plasma concentrations of both total and 
free ibuprofen after one, two, and three tablets 
are listed in Table I. Mean plasma concentra- 
tions of both total and free ibuprofen after the 
oral solution are listed in Table II. It should be 
noted that the one-compartment open model 
elaborated from mean plasma concentrations 
differs from the two-compartment open model 
elaborated from individual subject plasma con- 
centrations, as will be discussed in a future 
report. 
Table III lists kinetic parameters obtained 
from total and free ibuprofen plasma concentra- 
tions. The observed area under the plasma 
concentration-time curve, (AUC O-T, where 
T = 12 hr for tablets and 8 hr for solution), 
averaged 98% (range 96% to 99%) of the esti- 
mated AUC 0-00. Hence the area estimated by 
extrapolation, namely AUC T-00, was only a 
minor portion of AUC 0-00. 
In Table III there are eight mean elimination 
rate constants. An analysis of variance of all the 
individual elimination rate constants (n = 120) 
indicated no significant differences between the 
overall mean rate constant for total drug (0.316 
hr-i) and the overall mean rate constant for free 
drug (0.310 hr-'; P > .05). In contrast, signifi- 
cant differences were observed among treat- 
ment means (P < 0.001). In addition, the mean 
rate constant for tablets based on free ibuprofen 
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Table II. Mean plasma concentrations of 
total and free ibuprofen with their SEs 
after aqueous solution 
*Numbers in parentheses are SEs. 
plasma concentrations (0.297 hr-1) differed 
significantly (P < 0.05) from the correspond- 
ing mean rate constant for the solution (0.349 
hr--'). Considering the relative magnitudes of 
the mean rate constants, a likely explanation is 
that there is some continued absorption after the 
tablets in the time range in which elimination 
rate constants were estimated (usually the last 
three or four points). Thus rate constants from 
the solution are the most reliable. Mean rate 
constants following the solution, namely 0.370 
hr-1 from total ibuprofen and 0.349 hr-1 from 
free ibuprofen, correspond to harmonic mean 
elimination tihs of 1.87 hr and 1.98 hr. 
Oral Cis were calculated as the ratio of dose 
by assay per kilogram of body weight to the 
AUC 0-00. Values listed in Table III are oral Cis 
averaged over treatments. Fig. 1, a, is a plot of 
individual oral Cl from total drug (//kg x hr) vs 
assay dose (mg/kg). The line drawn through the 
0.0833 12.5 66.4 
(2.32)* (13.5) 
0.167 26.5 153 
(4.24) (28.0) 
0.25 33.0 195 
(4.24) (28.5) 
0.333 37.4 226 
(4.29) (29.6) 
0.5 36.2 214 
(3.00) (20.0) 
1.0 33.2 193 
(2.20) (14.8) 
1.5 30.2 171 
(1.68) (11.2) 
2.0 23.9 130 
(1.09) (6.01) 
3.0 16.3 86.5 
(0.66) (3.66) 
4.0 11.7 60.3 
(0.64) (3.52) 
6.0 5.82 29.1 
(0.46) (2.25) 
8.0 3.09 15.9 
(0.32) (1.66) 
Plasma concentration of ibuprofen 
Time Total Free 
(hr) ( pg (ng Iml) 
Table III. Mean kinetic parameters obtained from total and free ibuprofen plasma concentrations 
*Oral Cis are more properly written as CI, /F and Cl, IF where F is bioavailability. 
points is the least squares regression line; clear- 
ance from total plasma concentrations (C1t) = 
0.0349 + 0.00134 (dose). The slope of this line 
differed from zero (P < 0.001) by a t test. An 
analysis of variance showed highly signifi- 
cant differences among treatment means (P < 
0.0001). A paired t test, however, showed that 
the difference between mean Cis of 0.0419 and 
0.0426 //kg x hr for total drug after one tablet 
and the solution was not significant (P > 0.25). 
This indicated that Cl of total drug was dose 
dependent, with values increasing as the dose 
increased. An analysis of variance of oral Cl 
from free drug also showed significant differ- 
ences among treatment means (P = 0.019). At 
equivalent doses, however, a paired t test 
showed that differences between the mean Cl of 
7.83 and 7.75 //kg X hr for free drug after 
one tablet and the solution were not significant 
(P > 0.25). In addition, a plot of free Cl 
(/ /kg x hr) vs assay dose (mg/kg) (Fig. 1, b) 
resulted in a regression with a slope that was 
not significantly different from zero (0.1 > P > 
0.05). These results suggested that there was a 
small dose dependency for Cl based on free 
drug. Since oral Cl from free drug is the true Cl 
divided by the bioavailability, one possible ex- 
planation for the observed dependence of oral 
free Cl on dose is a slight decrease in the effi- 
ciency of absorption as the dose is increased. 
Estimates of bioavailability of one, two, and 
three tablets relative to the aqueous solution 
(calculated as ratios of free oral Cls) of 99%, 
90%, and 89% support this premise. Urinary 
recoveries of ibuprofen and its major metabo- 
lites, however, were consistent from treatment 
to treatment (Table IV). This indicates that uri- 
nary excretion of ibuprofen and its metabolites 
was a linear function of dose and any dose de- 
pendency associated with the absorption pro- 
cess was minor. 
Semilogarithmic plots of individual subject 
total and free plasma concentrations of ibupro- 
fen following one, two, and three tablets were 
constructed (not shown). In all cases it was 
found that the higher concentrations lie above 
the extrapolated log linear line that could be 
drawn through the terminal concentrations. This 
suggests applicability of the two-compartment 
open model with first-order absorption with rate 
Parameter 
Mean (SE) 
One tablet Two tablets Three tablets Solution 
Peak total plasma concentration 37.7 61.1 87.7 43.8 (s /m1) (2.16) (2.47) (4.84) (2.83) 
Peak free plasma concentration 221 403 688 269 
(ng /m1) (15.9) (23.5) (54.2) (22.2) 
Time of peak concentration 1.3 1.6 1.7 0.71 
(111) (0.23) (0.15) (0.21) (0.14) 
122 206 286 121 hr) (AUC 0-1)i (Et-mgi (4.85) (7.71) (12.3) (4.69) 
656 1197 1780 664 (AUC 0-T)f (1-n-ngi x hr) (30.6) (51.7) (82.7) (27.3) 
126 212 293 121 (AUC 0_00,d hr) (5.12) (7.89) (12.9) (4.69) 
680 1229 1816 711 (AUC 0- x)1(mn1 x hr) (31.7) (55.1) (86.4) (30.8) 
Elimination rate constant from 0.273 0.304 0.319 0.370 
total (hr-') (0.0066) (0.018) (0.012) (0.014) 
Elimination rate constant from free 0.271 0.307 0.314 0.349 
(hr-') (0.012) (0.015) (0.015) (0.015) 
Clt* of total / /(kg x hr) 0.0419 0.0498 0.0541 0.0426 
(0.002) (0.003) (0.003) (0.001) 
Clf* of free l /(kg x hr) 7.83 8.63 8.77 7.75 
(0.42) (0.45) (0.42) (0.26) 
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Fig. 2. Scatter plots of AUCs against milligram-per- 
kilogram dose. a, Total ibuprofen plasma AUC 
against dose. Curvilinear relationship is described by 
equation 1 in the text. b, Similar plot of free areas 
against dose. In this plot the function that best de- 
scribes data is given as equation 2. 
studied, but it does indicate the curvature in the 
data, particularly when theory indicates that 
(AUC 0-00)t should be equal to zero when the 
dose is equal to zero. 
Fig. 2, b, is a plot of individual subject area 
under the free ibuprofen plasma concentration 
time curve (AUC 0-00)f against the milligram- 
per-kilogram drug dose. No curvature was 
evident, suggesting a linear relationship be- 
tween free plasma concentrations of ibuprofen 
and the dose given. The equation of the line in 
Fig. 2, b, is: 
(AUC 0-00)f = 118 (dose) (2) 
Discussion 
Data presented indicate that nonlinearity of 
total ibuprofen plasma concentration data is the 
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Fig. 1. Plot of oral Cis against milligram-per-kilo- 
gram dose. a, Regression of oral Cl for total drug on 
dose. Least squares line has the equation Y = 
0.0349 + 0.001335X, r = 0.564 (P < 0.001). b, 
Regression of oral Cl from free drug on dose 
r = 0.261 (0.1 > P > 0.05). Line drawn represents 
mean Cl of 8.41 //(kg X hr). 
constant for absorption (ka) > > 0, and this 
will be shown in a future report. 
We knew that the area under the total ibupro- 
fen plasma concentration curve, (AUC 0-°C)t, 
increased less than proportionately with in- 
creases in dose. The mean (AUC 0-00)t values in 
Table III support this observation. Fig. 2,a, is a 
plot of individual subject (AUC 0-co)t values vs 
the drug dose measured in milligrams per kilo- 
gram. The line drawn through the points is em- 
pirical and is based on the least squares parabola 
forced through the origin (equation 1). 
(AUC 0-00)t = 26.6 (dose) 0.517 (dose)2 (1) 
This should not be considered a predictive 
function, particularly outside the dose range 
Table IV. Summary of urinary excretion data 
consequence of nonlinear plasma protein bind- 
ing of the drug. Although plots of total area 
against dose exhibit curvature (Fig. 2, a), plots 
of free area against dose are linear, and the line 
passes through the origin (Fig. 2, b). As a con- 
sequence of the nonlinear plasma protein bind- 
ing (which will be discussed in detail in a future 
report), both the oral Cl and bioavailability es- 
timated from total plasma concentrations are 
dose dependent. Both the oral Cl and bioavail- 
ability estimated from free plasma concentra- 
tions, however, are virtually dose independent. 
The consistency of the mean urinary recov- 
eries shown in Table IV, coupled with the 
statistical analyses of the complete data, indi- 
cated that urinary excretion of the ibuprofen me- 
tabolites was a linear function of dose and was 
consequently dose independent. These results, 
together with Fig. 2, b, and the Clf results 
shown in Table III, suggest that the efficiency 
of absorption of ibuprofen is dose independent. 
The dose dependence of the apparent elimi- 
nation rate constants was probably observed 
when absorption continued, to a minor degree, 
CH3 
- CH -COOH 
CH3 
- CH -COOH 
*There were no significant differences among treatment means for one, two, and three tablets in any given row when data were analyzed by 
analysis of variance for crossover design. 
fNumbers in parentheses are SEs. 
Structure of carboxy metabolite: H3C OH \ I C-CHz- / 
H3C 
§Structure of hydroxy metabolite: HOOC 
CH -CHz - 
H3C 
into the time region where rate constants were 
estimated, particularly for the tablet treatments. 
To ensure that this was introducing little if any 
bias into the estimated oral Cis, we also calcu- 
lated the extrapolated areas (AUC T-00)t and 
(AUC T-00)f by dividing the observed plasma 
concentration at 12 hr (for tablets) by the elimi- 
nation rate constant obtained for the same sub- 
ject after the solution was given. The resulting 
mean Cis, at, were 0.0417, 0.0494, and 
0.0541 //(kg x hr) for one, two, and three 
tablets, compared with the values 0.0419, 
0.0498, and 0.0541 //(kg x hr), shown in 
Table III and calculated by rate constants esti- 
mated from the tablet data. Similarly, by the 
revised method, mean Cls, Clf, were 7.97, 
8.49, and 8.83 //(kg x hr) for one, two, and 
three tablets, compared with 7.83, 8.63, and 
8.77 //(kg x hr), shown in Table III. Thus the 
extrapolated area relative to the total area is so 
small that the error introduced by a biased elim- 
ination rate constant is small and lacks sig- 
nificance. Both free and total ibuprofen plasma 
concentrations, at the tail end of the curves, 
Compound(s) 
Mean percent recovery in urine* 
One tablet Two tablets Three tablets Solution 
Unchanged ibuprofen 0 0.12 0.31 0 
(0.085)t (0.27) 
Conjugated ibuprofen 13.7 11.3 10.7 13.0 
(0.82) (1.11) (0.83) (1.32) 
Hydroxy metabolite$ 11.2 10.3 11.4 11.9 
(0.59) (0.72) (0.57) (1.45) 
Conjugated hydroxy metabolite 17.0 16.2 13.8 12.4 
(0.98) (1.55) (1.19) (1.39) 
Carboxy metabolite 30.1 27.7 30.9 27.2 
(1.60) (1.29) (1.24) (2.30) 
Conjugated carboxy metabolite 12.9 12.0 10.3 11.2 
(1.42) (1.63) (1.73) (1.88) 
Total recovery 84.9 77.7 77.4 75.7 
(3.02) (3.92) (3.46) (5.03) 
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declined exponentially at essentially the same 
rates, which has been explained theoretically by 
Wagner8 and Gibaldi and McNamara.3 No me- 
tabolites were detected in plasma. 
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